Methods, compositions, and systems for modulating coronavirus infection

JP2023549349A5Pending Publication Date: 2024-11-06LABORATORY CORPORATION OF AMERICA HOLDINGS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023528054
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-11
Filing Date
2021-11-11
Publication Date
2024-11-06

AI Technical Summary

Technical Problem

There is a need for effective treatment methods and therapeutic agents that can modulate and reduce the symptoms of viral infections, particularly those caused by SARS-CoV-2, and for assays to evaluate the effectiveness of potential treatments.

Method used

Methods and systems are developed to modulate the angiotensin converting enzyme 2 receptor (ACE-2) and nicotinic acetylcholine receptor (nAChR) to identify compounds that can affect the infectivity of SARS-CoV-2, using pseudovirions and luciferase-based assays to measure infectivity and neutralizing antibody responses.

Benefits of technology

These methods provide accurate, high-throughput assays that can be performed under BSL2 containment, reducing risks and costs, and help in assessing protective immunity, vaccine responses, and selecting convalescent plasma for therapy, while identifying compounds that modulate SARS-CoV-2 infectivity and neutralizing antibody production.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present disclosure relates to methods, compositions, and systems for evaluating compounds that can modulate coronaviruses (e.g., SARS CoV-2) and / or coronavirus infectivity. For example, methods are disclosed for identifying compounds that can modulate coronavirus infection, the methods comprising expressing angiotensin-converting enzyme 2 receptor (ACE-2) and / or nicotinic acetylcholine receptor (nAChR) receptors on target cells; contacting the target cells with viral particles containing at least a portion of the coronavirus spike protein in the absence and presence of the compound; and measuring the level of infection of the target cells to determine the infectivity of the viral particles in the presence or absence of the compound. Also disclosed are compounds identified using the methods, compositions, and systems, and methods of treatment.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Related applications This application claims priority to U.S. Provisional Application No. 63 / 112,290, filed November 11, 2020. The disclosure of U.S. Provisional Application No. 63 / 112,290 is incorporated herein by reference in its entirety.

[0002] field This disclosure relates to methods, compositions, and systems for the regulation of coronaviruses (e.g., SARS-CoV-2). [Background technology]

[0003] background The 2019 / 2020 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak in Wuhan, China, provided undeniable evidence that regional outbreaks of zoonotic viral infections have the potential to spread rapidly over much wider areas. Given the widespread distribution of the infection, SARS-CoV-2 may now be established as an endemic virus in the global population. The acute respiratory syndrome caused by SARS-CoV-2 was named coronavirus infection 2019 (COVID-19).

[0004] The SARS-CoV-2 spike (S) protein is a fusion protein found on the surface of virions that mediates entry into host cells. The S protein is a broadly glycosylated homotree in which each monomer is formed by a tree domain: head, stalk, and cytoplasmic tail. The head consists of two subunits: the S1 subunit is responsible for binding to angiotensin-converting enzyme 2 (ACE-2) in the host cell, and the S2 subunit is responsible for membrane fusion (Bosch et al., J. Virol., 2003, 77:8801-8811; Walls et al., Cell, 2020, 181:281-292.e286).

[0005] In recent years, given the low prevalence of smokers among hospitalized COVID-19 patients, it has been suggested that nicotine may offer some protective value in mitigating COVID-19. Further research has shown that the SARS-CoV-2 S protein can interact with nicotinic acetylcholine receptors (nAChRs) due to the fact that the S protein contains a sequence motif similar to known nAChR antagonists (Changeux, 2018, Philos. Trans. R. Soc. Lond. B. Biol. Sci., 373 (1749): 20170174; Oliveira et al., 2020, bioRxiv at https: / / doi.org / 10.1101 / 2020.07.16.206680). There are three main types of nAChRs: α4β2 nAChRs, primarily found in the brain; αβγδ nAChRs, primarily found in muscle; and α7 nAChRs, primarily found in CNS and immune cells (Oliveira, 2020). α7 nAChRs are homodimers, while the other two nAChRs are heterodimers. There is a need for treatments and therapies that can modulate and reduce the symptoms of viral infections (e.g., infection by SARS-CoV-2). Furthermore, there is a need for methods to assay the effectiveness of potential therapeutic agents for coronavirus infections (e.g., infection by SARS-CoV-2). [Prior art documents] [Non-patent literature]

[0006] [Non-Patent Document 1] Bosch et al., J. Virol., 2003, 77:8801-8811; Walls et al., Cell, 2020, 181:281-292.e286 [Non-Patent Document 2] Changeux, 2018, Philos. Trans. R. Soc. Lond. B. Biol. Sci., 373 (1749):20170174; [Non-Patent Document 3] Oliveira et al., 2020, bioRxiv at https: / / doi.org / 10.1101 / 2020.07.16.206680 [Overview of the project] [Means for solving the problem]

[0007] Abstract

[0008] This disclosure relates to methods, compositions, and systems for modulating coronaviruses (e.g., SARS-CoV-2). The disclosed methods, compositions, and systems can be embodied in a variety of ways. For example, in one embodiment, a method is disclosed for identifying a compound that can modulate infection by SARS-CoV-2, the method comprising the steps of: expressing angiotensin-converting enzyme 2 receptor (ACE-2) and / or nicotinic acetylcholine receptor (nAChR) on target cells; contacting the target cells with viral particles containing at least a portion of the SARS-CoV-2 spike protein in the absence and in the presence of the compound; and measuring the level of infection of the target cells in order to determine the infectivity of the viral particles in the presence or absence of the compound. Also disclosed are systems, compositions, and computer program products tangibly embodied in a non-temporary, machine-readable storage medium, including instructions configured to perform any of the steps of the above method or any part of the above system.

[0009] Brief explanation of the drawing This disclosure may be better understood by referring to the following non-limiting figures. [Brief explanation of the drawing]

[0010] [Figure 1]Figure 1 shows an exemplary assay for detecting SARS-CoV-2 neutralizing antibodies according to one embodiment of the present disclosure. PSV refers to pseudovirus; S-ORF refers to coronavirus S protein (envelope spike) open reading frame; ACE-2 refers to SARS-CoV and SARS-CoV-2 receptor (angiotensin-converting enzyme 2); TMPRSS2 refers to human transmembrane trypsin-like serine protease. Pseudovirions are shown as particles emitted from producer cells. [Figure 2] Figure 2 shows an example of in vitro target cells transfected with SARS CoV and SARS CoV-2 ACE-2 expression vectors and human transmembrane trypsin-like serine protease (TMPRSS2) expression vectors used to detect SARS CoV-2 infection according to one embodiment of the present disclosure. [Figure 3] Figure 3 shows an example of in vitro target cells transfected with a SARS-CoV-2 ACE-2 expression vector, a TMPRSS2 expression vector, and an AChR expression vector used to detect SARS-CoV-2 infection according to one embodiment of the present disclosure. ACE-2 refers to the SARS-CoV and SARS-CoV-2 receptor (angiotensin-converting enzyme 2); TMPRSS2 refers to human transmembrane trypsin-like serine protease; and AchR refers to the cholinergic receptor nicotinic α7 subunit (CHRNA7 or α7 nAChR). [Figure 4] Figure 4 shows that nAChR expression can modulate SARS-CoV-2 infectivity according to one embodiment of the present disclosure. [Modes for carrying out the invention]

[0011] Detailed explanation The following description outlines various aspects and embodiments of the compositions and methods of the present invention. No particular embodiment is intended to define the scope of the compositions and methods. Rather, the embodiments merely provide non-limiting examples of various methods and systems that fall within the scope of the compositions and methods. The description should be read and understood from the perspective of those skilled in the art; therefore, information well known to those skilled in the art is not necessarily included.

[0012] definition This disclosure is described here and in more detail thereafter. This disclosure may be embodied in many different forms and should not be construed as being limited to the aspects set forth herein; rather, these aspects are provided to satisfy the legal requirements for which this disclosure is available. Unless otherwise defined, all technical and scientific terms set forth herein have the same meaning as those generally understood by those skilled in the art to which this disclosure belongs. All patents, applications, published applications and other publications referenced herein are incorporated herein by reference in their entirety. If any definition set forth in this section conflicts with or otherwise does not agree with any definition set forth in the aforementioned patents, applications, published applications and other publications incorporated herein by reference, the definition set forth in this section shall prevail over the definitions incorporated herein by reference.

[0013] When introducing elements of the present disclosure or its embodiments, the articles "a", "an", "the", and "said" are intended to mean that one or more of the above elements are present. The terms "comprising", "including", and "having" are intended to be inclusive and mean that additional elements other than the recited elements may exist. It is understood that aspects and embodiments of the disclosure described herein include aspects and embodiments "consisting of" and / or "consisting essentially of".

[0014] The term "and / or" when used in a list of two or more items means that any one of the listed items can be used alone or in combination with any one or more of the listed items. For example, the expression "A and / or B" is intended to mean either A and B or both, i.e., only A, only B, or a combination of A and B. The expression "A, B, and / or C" is intended to mean only A, only B, only C, a combination of A and B, a combination of A and C, a combination of B and C, or a combination of A, B, and C.

[0015] Various aspects of the present disclosure are presented in a range format. It should be understood that the description in range format is for convenience and simplicity only and should not be construed as an immutable limitation to the scope of the present disclosure. Thus, a range description should be regarded as specifically disclosing all possible sub-ranges as well as the individual numerical values within that range. For example, a range description such as 1-6 should be regarded as specifically disclosing sub-ranges such as 1-3, 1-4, 1-5, 2-4, 2-6, 3-6, etc., as well as the individual numbers within that range (e.g., 1, 2, 3, 4, 5, and 6). This applies regardless of the width of the range.

[0016] The methods and systems of the present disclosure can be applied to various sample types. In certain embodiments, the sample includes a biological sample. In some embodiments, the biological sample is taken from a subject. In some embodiments, the subject can be a human subject. In some embodiments of the methods, the subject can be suspected of being exposed to a pathogen of any purpose. In certain embodiments, the pathogen is SARS-CoV-2. As used herein, the terms "subject" and "patient" are used interchangeably. As used herein, the term "subject" refers to an animal, preferably a mammal (non-primates (e.g., cows, pigs, horses, donkeys, goats, camels, cats, dogs, guinea pigs, rats, mice or sheep) and primates (e.g., monkeys (e.g., cynomolgus monkeys, gorillas, chimpanzees, or humans) are included)).

[0017] The terms “sample,” “patient sample,” “biological sample,” or “specimen” are interchangeable as used herein. A sample source may be a solid tissue, such as fresh tissue, frozen and / or preserved organ or tissue, or a biopsy or aspirate. A sample source may be a liquid sample. Non-limiting examples of liquid samples include cell-free nucleic acids, blood or blood products (e.g., serum, plasma), urine, nasal swabs, biopsy samples (e.g., liquid biopsies), or combinations thereof. The term “blood” encompasses whole blood, blood products, or any fraction of blood as conventionally defined (e.g., serum, plasma, buffy coat). For example, in a particular embodiment (e.g., COVID-19), the biological sample may include a specimen of either the upper or lower respiratory system. In one embodiment, the sample may include, for example, at least one of nasopharyngeal swabs, middle turbinate swabs, anterior nostril swabs, oropharyngeal swabs, sputum, lower respiratory tract aspirates, bronchoalveolar lavage materials, nasopharyngeal lavage materials and / or aspirates, or nasal aspirates. The sample may include compounds that are not naturally mixed with tissues, such as preservatives, anticoagulants, buffers, fixatives, nutrients, and antibiotics.

[0018] The term "treatment" and other forms of this phrase refer to the administration of drugs to alleviate a disease or its symptoms. Treatment can also refer to any process that a person skilled in the art (e.g., a physician performing the treatment) would consider advisable.

[0019] Method for detecting compounds that modulate SARS infectivity One embodiment is a method for identifying a compound that can modulate infection by coronavirus, the method comprising the steps of: expressing angiotensin-converting enzyme 2 receptor (ACE-2) and / or nicotinic acetylcholine receptor (nAChR) on target cells; contacting the target cells with viral particles containing at least a portion of the spike protein in the absence and in the presence of the compound; and measuring the level of infection of the target cells in order to determine the infectivity of the viral particles in the presence or absence of the compound. In some aspects, the coronavirus is SARS-CoV-2. There are many mutant strains of SARS-CoV-2. In some embodiments, the SARS-CoV-2 is a mutant strain, which is a delta mutant, alpha mutant, beta mutant, gamma mutant, epsilon mutant, eta mutant, iota mutant, kappa mutant, 1.617.3 mutant, mu mutant, or zeta mutant. In some embodiments, the mutant strain is a delta mutant. In other contexts, the above coronavirus is either SARS-CoV or seasonal human coronavirus NL63.

[0020] In certain embodiments of these methods, the viral particles are HIV pseudovirions. For example, in one embodiment, the method is as disclosed herein by PhenoSense (登録商標) (PS) A CoV neutralizing antibody (nAb) assay format may be used. Alternatively, the above assay may be used in a manner that is not limited to replacing the neutralizing antibody (or subject (e.g., patient) serum) with a compound to be evaluated for its antiviral activity. (登録商標) A CoV Assay can be used. In a particular embodiment, the above nAChR is α7 nAChR.

[0021] Therefore, a method for identifying compounds that can modulate SARS-CoV-2 infection, wherein the above method is (a) To producer cells, i) Nucleic acids encoding the SARS-CoV-2 spike protein or a portion thereof, and ii) A genomic viral expression vector containing a sequence derived from a second virus that is not a coronavirus and contains an indicator nucleic acid that generates a detectable signal, The process of transfecting; (b) Incubating the transfected producer cells under conditions that generate pseudovirions containing the SARS-CoV-2 spike protein or a portion thereof; (c) A step of bringing the pseudovirion of step (b) above into contact with target cells under conditions that allow the pseudovirion to infect the target cells, and in or out of the presence of the compound, wherein the target cells express angiotensin-converting enzyme 2 receptor (ACE-2) and / or nicotinic acetylcholine receptor (nAChR); and (d) A step of measuring the amount of detectable signal produced by the target cell in order to determine the infectivity of the virus particle in the presence or absence of the compound, A method of inclusion is disclosed.

[0022] In some embodiments, the SARS-CoV-2 is a mutant strain, which is a delta mutant, alpha mutant, beta mutant, gamma mutant, epsilon mutant, eta mutant, iota mutant, kappa mutant, 1.617.3 mutant, muu mutant, or zeta mutant. In some embodiments, the mutant strain is a delta mutant.

[0023] In other aspects of these methods, the above methods are used to identify compounds that can modulate infection by another coronavirus (e.g., SARS-CoV or seasonal human coronavirus NL63). In these aspects, the nucleic acid in step (a)(i) instead encodes a spike protein or a portion thereof derived from SARS-CoV or seasonal human coronavirus NL63.

[0024] In certain embodiments, the second virus is human immunodeficiency virus (HIV) or a genetically modified HIV. For example, the HIV may be modified to remove the genomic sequence encoding the HIV envelope protein. Also, in certain embodiments, the nAChR is α7 nAChR.

[0025] In yet another embodiment, a method for determining the effectiveness of a compound that modulates the production of SARS-CoV-2 neutralizing antibodies in a subject, wherein the method is (a) The step of expressing angiotensin-converting enzyme 2 receptor (ACE-2) and / or nicotinic acetylcholine receptor (nAChR) on target cells; (b) A step of contacting the target cells and, optionally, viral particles containing at least a portion of the SARS CoV-2 spike protein derived from the subject, in the absence and presence of (i) a first sample obtained from the subject before treatment with the compound, and (ii) a second sample obtained from the subject after treatment with the compound, wherein the first and second samples include antibodies; and (c) A step of measuring the infection level of target cells in order to determine the infectivity of the virus particles in the presence of the first or second subject sample, in order to determine a change in the activity or amount of neutralizing antibodies in the first and second samples of the subject, wherein a change in the activity or amount of neutralizing antibodies present in the sample is detected as a change in the infectivity of the virus particles. A method of inclusion is disclosed.

[0026] In some embodiments, the SARS-CoV-2 is a mutant strain, which is a delta mutant, alpha mutant, beta mutant, gamma mutant, epsilon mutant, eta mutant, iota mutant, kappa mutant, 1.617.3 mutant, muu mutant, or zeta mutant. In some embodiments, the mutant strain is a delta mutant.

[0027] In other aspects of these methods, the methods described above are used to determine the efficacy of compounds that modulate the production of neutralizing antibodies against another coronavirus (e.g., SARS-CoV or seasonal human coronavirus NL63). In these aspects, the viral particles in step (b) above include at least a portion of the spike protein of SARS-CoV or seasonal human coronavirus NL63.

[0028] In one embodiment, the viral particle is an HIV pseudovirion. For example, the HIV may be modified to remove the genome sequence encoding the HIV envelope protein. In a particular embodiment, the nAChR is an α7 nAChR.

[0029] In yet another embodiment, a method for determining the effectiveness of a compound that modulates the production of SARS-CoV-2 neutralizing antibodies in a subject, wherein the method is (a) To PSV producer cells, i) A nucleic acid encoding the SARS-CoV-2 spike protein or a portion thereof, derived from the above-mentioned subject, and ii) A genomic viral expression vector containing a sequence derived from a second virus that is not a coronavirus and contains an indicator nucleic acid that generates a detectable signal, The process of transfecting; (b) Incubating the transfected producer cells under conditions that cause the producer cells to produce pseudovirions containing the SARS-CoV-2 spike protein or a portion thereof; (c) A step of contacting the pseudovirion of step (b) above with target cells in the presence or absence of (i) a first sample obtained from the subject before treatment with the compound, and (ii) a second sample obtained from the subject after treatment with the compound, wherein the first and second samples comprise antibodies, and the target cells express angiotensin-converting enzyme 2 receptor (ACE-2) and / or nicotinic acetylcholine receptor (nAChR) under conditions that allow the pseudovirion to infect the target cells; (d) A step of measuring the amount of a detectable signal produced by the target cells in the presence of the first and second samples of the subject in order to determine a change in the activity or amount of the neutralizing antibody in the first and second samples of the subject, wherein the change in the activity or amount of the neutralizing antibody is detected as a change in the infectivity of the virus particles. A method of inclusion is disclosed.

[0030] In some embodiments, the SARS-CoV-2 is a mutant strain, which is a delta mutant, alpha mutant, beta mutant, gamma mutant, epsilon mutant, eta mutant, iota mutant, kappa mutant, 1.617.3 mutant, muu mutant, or zeta mutant. In some embodiments, the mutant strain is a delta mutant.

[0031] In other aspects of these methods, the methods described above are used to determine the efficacy of compounds that modulate the production of neutralizing antibodies against another coronavirus (e.g., SARS-CoV or seasonal human coronavirus NL63). In these aspects, the nucleic acid in step (a)(i) encodes the spike protein or a portion thereof of SARS-CoV or seasonal human coronavirus NL63 derived from the subject.

[0032] In certain embodiments, the second virus is HIV or a genetically modified HIV. For example, the HIV may be modified to remove the genomic sequence encoding the HIV envelope protein. Also, in certain embodiments, the nAChR is an α7 nAChR.

[0033] Composition for detecting compounds that modulate coronavirus infectivity Compositions and systems for detecting compounds that can modulate coronavirus infectivity (e.g., infectivity by SARS-CoV-2, SARS-CoV, or NL63) are also disclosed herein. In some embodiments, the SARS-CoV-2 is a mutant strain, which is a delta mutant, alpha mutant, beta mutant, gamma mutant, epsilon mutant, eta mutant, iota mutant, kappa mutant, 1.617.3 mutant, muu mutant, or zeta mutant. In some embodiments, the mutant strain is a delta mutant.

[0034] In one embodiment, the composition may comprise cells manipulated to be either producer cells or target cells as disclosed herein. For example, the system may comprise a first cell genetically modified to be a target cell expressing angiotensin-converting enzyme 2 receptor (ACE-2) and / or nicotinic acetylcholine receptor (nAChR). In one embodiment, the target cell may similarly be genetically modified to express human transmembrane trypsin-like serine protease (TMPRSS2).

[0035] Furthermore and / or alternatively, the above composition may include producer cells. In certain embodiments, the producer cells may be genetically modified second cells produced by the following steps: to the second cells: i) transfecting a genomic viral expression vector containing a nucleic acid encoding the SARS CoV-2 spike protein or a portion thereof, and ii) a sequence derived from a second virus, which is not a coronavirus and optionally contains an indicator nucleic acid that generates a detectable signal. In one embodiment, the coronavirus spike protein is the coronavirus S protein. In some embodiments, the SARS CoV-2 is a mutant strain, and the mutant strain is a delta mutant, alpha mutant, beta mutant, gamma mutant, epsilon mutant, eta mutant, iota mutant, kappa mutant, 1.617.3 mutant, mu mutant, or zeta mutant. In some embodiments, the mutant strain is a delta mutant. In other aspects of these producer cells, the nucleic acid in (i) above encodes the spike protein or a portion thereof derived from SARS CoV or seasonal human coronavirus NL63.

[0036] In certain embodiments, the second virus is HIV or a genetically modified HIV. For example, the HIV may be modified to remove the genomic sequence encoding the HIV envelope protein. Also, in certain embodiments, the nAChR is α7 nAChR, or other nAChRs may be used. Furthermore, in some embodiments, the target cells further express human transmembrane trypsin-like serine protease (TMPRSS2).

[0037] Various constructs can be used as indicator nucleic acids. In certain embodiments, the indicator nucleic acid includes an indicator gene. For example, the indicator gene may be a luciferase gene.

[0038] In certain embodiments, the S protein is derived from a subject infected with a coronavirus. In certain embodiments, the subject is infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In some embodiments, the SARS-CoV-2 is a mutant strain, which may be a delta mutant, alpha mutant, beta mutant, gamma mutant, epsilon mutant, eta mutant, iota mutant, kappa mutant, 1.617.3 mutant, mu mutant, or zeta mutant. In some embodiments, the mutant strain is a delta mutant. In other embodiments, the subject is infected with SARS-CoV or NL63.

[0039] Various cells may be used to generate the target cells or producer cells. In certain embodiments, the producer cells and / or target cells are mammalian cells. In some embodiments, the producer cells and / or target cells are human cells. In some cases, the producer cells and / or target cells are human embryonic kidney (HEK) cells, such as 293 HEK cells.

[0040] System for detecting compounds that can modulate coronavirus Also disclosed are a system for performing any of the steps of the disclosed method, and / or using any of the disclosed compositions and computer-implemented instructions to perform any of the steps of the disclosed method, and / or using any of the disclosed compositions or performing any of the parts of the disclosed system.

[0041] Accordingly, the system may include cells engineered to be either producer cells or target cells as disclosed herein. For example, the system may include target cells engineered to express angiotensin-converting enzyme 2 receptor (ACE-2) and / or nicotinic acetylcholine receptor (nAChR). The system may further include stations and / or components for bringing the target cells and viral particles containing at least a portion of the SARS-CoV-2 spike protein into contact in the absence and in the presence of a compound to be tested as a potential regulator of SARS-CoV-2 infectivity. In one embodiment, the compound may be a subject or patient sample thought to contain a neutralizing antibody. Furthermore, the system may include stations and / or components for measuring the level of infection of the target cells in order to determine the infectivity of the viral particles in the presence or absence of the compound. In one embodiment, the infected cells may contain a detectable marker. For example, in one embodiment, the target cells may contain luciferase. Alternatively, the viral particles may contain luciferase. Accordingly, in certain embodiments, the system may include a station for measuring the signal from luciferase resulting from the infection of the target cells. In some embodiments, the SARS-CoV-2 is a mutant strain, and the mutant strain is a delta mutant, alpha mutant, beta mutant, gamma mutant, epsilon mutant, eta mutant, iota mutant, kappa mutant, 1.617.3 mutant, mu mutant, or zeta mutant. In some embodiments, the mutant strain is a delta mutant. In other embodiments, the viral particle contains at least a portion of the spike protein of NL63 instead of SARS-CoV or SARS-CoV-2.

[0042] As disclosed herein, in certain embodiments, the viral particles are HIV pseudovirions. For example, in one embodiment, the method is as disclosed herein by PhenoSense(登録商標) (PS) A CoV neutralizing antibody (nAb) assay format may be used. Alternatively, the above assay may be performed using PhenoSense, except that the neutralizing antibody (or subject, e.g., patient's serum) is replaced with a compound to be evaluated for its antiviral activity. (登録商標) CoV assays can be used. In a particular embodiment, the above nAChR is α7 nAChR.

[0043] Accordingly, the system may, in a particular embodiment, include genetically modified producer cells. In a particular embodiment, the producer cells may be produced by transfecting the producer cells with a genomic viral expression vector containing i) a nucleic acid encoding the SARS CoV-2 spike protein or a portion thereof (or, instead, a spike protein or a portion thereof derived from SARS CoV or NL63), and ii) a sequence derived from a second virus that is not a coronavirus and contains an indicator nucleic acid that generates a detectable signal. The system may further include stations and / or components for incubating the producer cells under conditions that cause a pseudovirion containing the SARS CoV-2 spike protein or a portion thereof (or, instead, a spike protein or a portion thereof derived from SARS CoV or NL63) to be produced. The system may also include stations and / or components for bringing the pseudovirion produced by the producer cells into contact with target cells under conditions that cause the pseudovirion to infect the target cells, and in or out of the presence of a compound to be tested as a potential regulator of coronavirus infectivity. In one embodiment, the compound may be a subject or patient sample thought to contain a neutralizing antibody. In a particular embodiment, the target cells express angiotensin-converting enzyme 2 receptor (ACE-2) and / or nicotinic acetylcholine receptor (nAChR). Furthermore, the system may include a station for measuring the level of infection of the target cells in order to determine the infectivity of the viral particles in or out of the presence of the compound. In one embodiment, the infected cells may contain a detectable marker. For example, in one embodiment, the target cells may contain luciferase. Alternatively, the viral particles may contain luciferase. Therefore, in a particular embodiment, the system may include a station for measuring the signal from luciferase resulting from the infection of the target cells.

[0044] In some embodiments, the system or any of the stations of the system further includes a computer and / or a data processor. In a particular embodiment, the system may include a computer product tangibly embodied in a non-temporary computer-readable storage medium, which, when run on one or more computers and / or the one or more data processors, includes instructions causing the one or more data processors to perform the method described above or to perform an act causing the system of any of the embodiments disclosed herein. One or more embodiments described herein may be executed using program modules, engines, or components. Program modules, engines, or components may include programs, subroutines, parts of programs, or software or hardware components capable of performing one or more of the described tasks or functions. As used herein, a module or component may reside in a hardware component independently of other modules or components. Alternatively, a module or component may be a shared element or process of other modules, programs, or machines. For example, as will be considered below, the system may include a computer program product tangibly embodied in a computer and / or a non-temporary, machine-readable storage medium to correlate changes in the infectivity of the virus particles or pseudovirions. Thus, in a particular embodiment, the system may include components for quantifying the measurements. The system may also include components for performing statistical analysis of the data.

[0045] Also disclosed are computer program products tangibly embodied in a non-temporary, machine-readable storage medium, which include instructions configured to perform steps of any of the methods of performing the above system and / or any of the disclosed embodiments. In one embodiment, the system includes computer program products tangibly embodied in a non-temporary, machine-readable storage medium, which include instructions configured to determine a change in coronavirus (e.g., SARS-CoV-2) infectivity caused by a compound of interest. Furthermore and / or alternatively, the computer program products may include instructions for determining a change in the neutralizing antibody response resulting from treatment with the compound of interest. [Examples]

[0046] Examples Example 1 - Detection of SARS-CoV-2 neutralizing antibodies The pathogenicity of SARS-CoV-2 requires that all cell-based in vitro studies involving live (i.e., reproducible) virus, including the assessment of nAb activity, be performed under BSL3 containment. The assays disclosed herein provide an accurate, reproducible, and high-throughput alternative that can be performed under BSL2 containment, resulting in reduced risk for laboratory personnel, as well as lower costs for vaccine sponsors and convalescent serum providers.

[0047] Such assays allow testing to establish protective immunity levels against SARS-CoV-2, contribute to predicting individual prognosis, and monitor recovery after infection with the pathogen. Furthermore, these assays can be used to test vaccine and treatment responses, as well as to assist in the selection of donor plasma for convalescent plasma therapy. Currently available assays are insufficient for these applications.

[0048] The above PS CoV nAb assay was developed to evaluate antiretroviral drug susceptibility (Petropoulos et al., AAC 2000) and later adapted to evaluate entry inhibitors, nAb activity (Richman et al., PNAS 2003) and co-receptor tropism (Whitcomb et al., 2007). It is a proprietary work of PhenoSense. (登録商標) It is being developed by utilizing the Assay platform. Luciferase production depends on viral entry and the completion of one viral replication cycle. Drugs that inhibit pseudoviral entry or replication reduce luciferase activity in a dose-dependent manner, providing a quantitative measure of drug and antibody sensitivity. Over time, the above-mentioned PhenoSense (登録商標) The assay platform was successfully adapted to evaluate vaccines and entry inhibitors that target various enveloped viruses (including orthomyxoviruses (influenza A and B), paramyxoviruses (RSV A and B), filoviruses (Ebola), and most recently, coronaviruses (SARS-CoV-2, SARS-CoV, NL63)).

[0049] As shown in Figure 1, PhenoSense (登録商標) The measurement of nAb activity using the SARS CoV-2 nAb Assay is performed by generating HIV-1 pseudovirions expressing the SARS CoV-2 spike protein. These pseudovirions can be generated by transfecting cells (e.g., HEK293 cells) with an HIV-1 genome vector and a SARS CoV-2 envelope expression vector expressing the S protein (S-ORF), thereby generating producer cells that enable the generation of HIV pseudovirions expressing the SARS CoV-2 S protein.

[0050] The above assay also includes target cells generated by transfecting cells (e.g., HEK293 cells) with an angiotensin-converting enzyme 2 (ACE-2) expression vector and a human airway transmembrane trypsin-like serine protease (TMPRSS) expression vector. ACE-2 is the receptor for SARS CoV and SARS CoV-2 (Figures 1 and 2). Thus, the above target cells are susceptible to infection by HIV pseudovirions expressing the SARS CoV-2 S protein. Infection can be quantified by the expression of luciferase (present in the above pseudovirions).

[0051] To perform the above assay, target cells are infected with the above pseudovirions in the presence or absence of serum derived from a subject. Thus, upon infection of target cells expressing both (ACE-2) and TMPRSS2, neutralizing antibody activity is measured by evaluating the inhibition of luciferase activity in HEK293 target cells expressing the ACE2 receptor after pre-incubating the above pseudovirions with serial dilutions of the serum sample.

[0052] Data can be shown by plotting the percent inhibition of luciferase activity against the log10 reciprocal of serum / plasma dilution, and the nAb titer is reported as the reciprocal of the serum dilution rate that confers 50% inhibition (ID 50 ) of pseudovirus infection. This can be expressed as follows: % inhibition = 100% - (((RLU(vector + sample + diluent) - RLU(background)) / (RLU(vector + diluent) - RLU(background))) × 100%). The results of PhenoSense SARS CoV-2 nAb are ID 50The titer (1 / dilution ratio) or qualitatively (positive, negative) based on a predetermined dilution ratio cutoff (e.g., >50% inhibition at a 1:40 dilution) may be reported. To ensure that the measured nAb activity is SARS-CoV-2 nAb specific, each test specimen is also evaluated using nonspecific pseudoviruses (specificity control) expressing the non-reactive envelope protein of one or more unrelated viruses (e.g., avian influenza virus).

[0053] Example 2 - Co-transfection of target cells in nAChR Using the assay described in Example 1, it was determined that the α7 nicotinic acetylcholine receptor (nAChR) modulates the infectivity of HIV pseudovirions expressing the SARS-CoV-2 S protein. In these experiments, the assay was performed as described in Example 1, with the target cells transfected with an AChR expression vector and further expressed in the target cells with α7 nAChR along with ACE-2 and TMPRSS2 (Figure 3). Co-expression of nAChR with ACE-2 was found to increase infectivity (as measured by increased luciferase activity) (Figure 4).

[0054] Example 3 - Embodiment A1. A method for identifying compounds that can modulate infection by coronavirus, wherein the method is: A step of expressing angiotensin-converting enzyme 2 receptor (ACE-2) and / or nicotinic acetylcholine receptor (nAChR) on target cells; A step of bringing the target cells and virus particles containing at least a portion of the coronavirus spike protein into contact in the absence and in the presence of the compound; and A step of measuring the infection level of the target cells in order to determine the infectivity of the virus particles in the presence or absence of the compound, A method of including. A2. The method according to Embodiment A1, wherein the coronavirus is SARS-CoV-2. A3. The method according to Embodiment A2, wherein the SARS-CoV-2 is a mutant strain, and the mutant strain is a delta mutant, alpha mutant, beta mutant, gamma mutant, epsilon mutant, eta mutant, iota mutant, kappa mutant, 1.617.3 mutant, muu mutant, or zeta mutant. A4. The method according to Embodiment A1, wherein the coronavirus is SARS-CoV or NL63. A5. The method according to any one of Embodiments A1 to A4, wherein the virus particle is an HIV pseudovirion. A6. The method according to any one of embodiments A1 to A5, wherein the nAChR is α7 nAChR.

[0055] B1. A method for determining the effectiveness of a compound that modulates the production of coronavirus neutralizing antibodies in a test subject, wherein the method is: A step of expressing angiotensin-converting enzyme 2 receptor (ACE-2) and / or nicotinic acetylcholine receptor (nAChR) receptor on target cells; A step of contacting target cells and, optionally, virus particles derived from the subject, which include at least a portion of the coronavirus spike protein, in the absence and presence of (i) a first sample obtained from the subject before treatment with the compound, and (ii) a second sample obtained from the subject after treatment with the compound, wherein the first and second samples include antibodies; and A step of measuring the infection level of target cells in order to determine the change in the activity or amount of neutralizing antibodies in the first and second samples of the subject in order to determine the infectivity of the virus particles in the presence of the first and second subject samples, wherein the change in the activity or amount of neutralizing antibodies is detected as a change in the infectivity of the virus particles. A method of including. B2. The method according to embodiment B1, wherein the coronavirus is SARS-CoV-2. B3. The method according to Embodiment B2, wherein the SARS-CoV-2 is a mutant strain, and the mutant strain is a delta mutant, alpha mutant, beta mutant, gamma mutant, epsilon mutant, eta mutant, iota mutant, kappa mutant, 1.617.3 mutant, muu mutant, or zeta mutant. B4. The method according to Embodiment B1, wherein the coronavirus is SARS-CoV or NL63. B5. The method according to any one of the embodiments described above or below, wherein the virus particle is an HIV pseudovirion. B6. The method according to any one of the embodiments described above or below, wherein the nAChR is α7 nAChR. B7. The method according to any one of the embodiments described above or below, wherein the coronavirus spike protein is the coronavirus S protein. B8. The method according to any one of the embodiments described above or below, wherein the indicator nucleic acid includes an indicator gene. B9. The method according to any one of the embodiments described above or below, wherein the indicator gene is a luciferase gene. B10. The method according to any one of the embodiments described above or below, wherein the subject is infected with or has been infected with the coronavirus. B11. The method according to any one of the embodiments described above or below, wherein the subject is infected with or has been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). B12. The method according to any one of the embodiments described above or below, wherein the subject is infected with or has been infected with SARS-CoV or NL63. B13. The method according to any one of the embodiments described above or below, wherein the producer cells and / or the target cells are mammalian cells. B14. The method according to any one of the embodiments described above or below, wherein the producer cells and / or the target cells are human cells. B15. The method according to any one of the embodiments described above or below, wherein the producer cells and / or the target cells are human embryonic kidney cells. B16. The method according to any one of the embodiments described above or below, wherein the human embryonic kidney cells are 293 (HEK293) cells. B17. The method according to any one of the embodiments described above or below, wherein the sample is serum or plasma. B18. The method according to any one of the embodiments described above or below, wherein the target cells further express human transmembrane trypsin-like serine protease (TMPRSS2). B19. The method according to any one of the embodiments described above or below, wherein the compound is an nAChR antagonist.

[0056] C1. A method for identifying compounds that can modulate coronavirus infection, wherein the method is: (a) To producer cells, i) nucleic acids encoding the coronavirus spike protein or a portion thereof, and ii) A genomic viral expression vector containing a sequence derived from a second virus that is not a coronavirus and contains an indicator nucleic acid that generates a detectable signal, The process of transfecting; (b) Incubating the transfected producer cells under conditions that generate pseudovirions containing the coronavirus spike protein or a portion thereof; (c) A step of bringing the pseudovirion of step (b) into contact with a target cell under conditions that cause the pseudovirion to infect the target cell, and in or out of the presence of the compound, wherein the target cell expresses angiotensin-converting enzyme 2 receptor (ACE-2) and / or nicotinic acetylcholine receptor (nAChR); and (d) A step of measuring the amount of detectable signal produced by the target cell in order to determine the infectivity of the virus particle in the presence or absence of the compound, A method of including. C2. The method according to embodiment C1, wherein the coronavirus is SARS-CoV-2. C3. The method according to Embodiment C2, wherein the SARS-CoV-2 is a mutant strain, and the mutant strain is a delta mutant, alpha mutant, beta mutant, gamma mutant, epsilon mutant, eta mutant, iota mutant, kappa mutant, 1.617.3 mutant, muu mutant, or zeta mutant. C4. The method according to embodiment C1, wherein the coronavirus is SARS-CoV or NL63. C5. The method according to any one of embodiments C1 to C4, wherein the nAChR is α7 nAChR. C6. The method according to any one of embodiments C1 to C5, wherein the second virus is HIV or a genetically modified HIV. C7. The method according to any one of the embodiments described above, wherein the compound is an nAchR antagonist.

[0057] D1. A method for determining the effectiveness of a compound that modulates the production of coronavirus neutralizing antibodies in a test subject, wherein the method is: (a) To producer cells, i) nucleic acids, if necessary, that encode the coronavirus spike protein or a portion thereof, derived from the subject, and ii) A genomic viral expression vector containing a sequence derived from a second virus that is not a coronavirus and contains an indicator nucleic acid that generates a detectable signal, The process of transfecting; (b) Incubating the transfected producer cells under conditions that cause the producer cells to produce pseudovirions containing the coronavirus spike protein or a portion thereof; (c) A step of contacting the pseudovirion of step (b) with target cells in the presence or absence of (i) a first sample obtained from the subject before treatment with the compound, and (ii) a second sample obtained from the subject after treatment with the compound, wherein the target cells express angiotensin-converting enzyme 2 receptor (ACE-2) and / or nicotinic acetylcholine receptor (nAChR) under conditions that allow the pseudovirion to infect the target cells; (d) A step of measuring the amount of a detectable signal produced by the target cells in the presence of the first and second samples of the subject in order to determine a change in the activity or amount of the neutralizing antibody in the first and second samples of the subject, wherein the change in the activity or amount of the neutralizing antibody is detected as a change in the infectivity of the virus particles. A method of including. D2. The method according to embodiment D1, wherein the coronavirus is SARS-CoV-2. D3. The method according to Embodiment D2, wherein the SARS-CoV-2 is a mutant strain, and the mutant strain is a delta mutant, alpha mutant, beta mutant, gamma mutant, epsilon mutant, eta mutant, iota mutant, kappa mutant, 1.617.3 mutant, muu mutant, or zeta mutant. D4. The method according to embodiment D1, wherein the coronavirus is SARS-CoV or NL63. D5. The method according to any one of embodiments D1 to D4, wherein the nAChR is α7 nAChR. D6. The method according to any one of embodiments D1 to D5, wherein the second virus is HIV or a genetically modified HIV. D7. The method according to any one of the embodiments described above or below, wherein the compound is an nAchR antagonist.

[0058] E1. A station and / or system comprising genetically modified cells for performing any of the steps of any of the embodiments described above, or for using any one of the compositions of any of the embodiments described below.

[0059] F1. A computer program product tangibly embodied in a non-temporary, machine-readable storage medium, which includes instructions configured to perform any of the steps of any of the embodiments described above, or to use any one of the compositions of any of the embodiments described below, or to perform any part of the system of Embodiment E1.

[0060] G1. Compositions for the detection of compounds that can modulate the infectivity of coronaviruses (e.g., SARS-CoV-2). G2. The composition according to Embodiment G1, wherein the coronavirus is SARS-CoV-2. G3. The composition according to Embodiment G2, wherein the SARS-CoV-2 is a mutant strain, and the mutant strain is a delta mutant, alpha mutant, beta mutant, gamma mutant, epsilon mutant, eta mutant, iota mutant, kappa mutant, 1.617.3 mutant, muu mutant, or zeta mutant. G4. The composition according to Embodiment G1, wherein the coronavirus is SARS-CoV or NL63. G5. The composition according to any one of the embodiments described above or below, comprising cells that have been genetically modified to be either producer cells or target cells. G6. The composition according to any one of the embodiments described above or below, comprising a first cell that has been genetically modified to be a target cell expressing angiotensin-converting enzyme 2 receptor (ACE-2) and / or nicotinic acetylcholine receptor (nAChR). G7. The composition according to any one of the embodiments described above or below, wherein the target cells are genetically modified to express human transmembrane trypsin-like serine protease (TMPRSS2). G8. A composition according to any one of the embodiments described above or below, comprising producer cells. G9. The composition according to any one of the embodiments described above or below, wherein the producer cells are genetically modified second cells that express a second virus or a part thereof, which is not a coronavirus and contains an indicator nucleic acid that produces a detectable signal. G10. The composition according to any one of the embodiments described above or below, wherein the producer cells generate a pseudovirion containing the coronavirus spike protein or a portion thereof. G11. The composition according to any one of the embodiments described above or below, wherein the coronavirus spike protein is the coronavirus S protein. G12. The composition according to any one of the embodiments described above or below, wherein the S protein is derived from a subject infected with coronavirus. G13. The subject is infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the composition is as described in any one of the embodiments described above or below. G14. The composition according to any one of the embodiments described above or below, wherein the subject is infected with SARS-CoV and / or NL63. G15. The composition according to any one of the embodiments described above or below, wherein the second virus is HIV or a genetically modified HIV. G16. The composition according to any one of the embodiments described above or below, wherein the nAChR is α7 nAChR. G17. The indicator nucleic acid is a composition according to any one of the embodiments described above or below, comprising an indicator gene. G18. The composition according to any one of the embodiments described above or below, wherein the indicator gene is a luciferase gene. G19. The composition according to any one of the embodiments described above or below, wherein the producer cells and / or target cells are mammalian cells. G20. The composition according to any one of the embodiments described above or below, wherein the producer cells and / or the target cells are human cells. G21. The composition according to any one of the embodiments described above or below, wherein the producer cells and / or target cells are human embryonic kidney (HEK) cells. G22. The composition according to any one of the embodiments described above or below, wherein the human embryonic kidney cells are HEK 293 cells. G23. The composition according to any of the above embodiments, wherein the compound is an nAchR antagonist.

[0061] H1. A compound identified using any one of the embodiments described above.

[0062] I1. A treatment method comprising the step of using the compound described in H1 to reduce or prevent symptoms of SARS-CoV-2 infection. I2. A treatment method comprising the step of using the compound described in H1 to reduce or prevent symptoms of SARS-CoV infection and / or NL63 infection.

[0063] J1. A treatment method comprising the step of administering to a subject or patient an inhibitor that interferes with the binding or interaction between SARS-CoV-2 and the AchR receptor in the subject or patient. J2. A treatment method comprising the step of administering to a subject or patient an inhibitor that interferes with the binding or interaction between SARS CoV or NL63 and the AchR receptor in the subject or patient.

Claims

1. 1. A method for identifying a compound capable of modulating infection by a coronavirus, the method comprising: expressing angiotensin-converting enzyme 2 receptor (ACE-2) and / or nicotinic acetylcholine receptor (nAChR) receptors on the target cells; contacting said target cell with a viral particle comprising at least a portion of said coronavirus spike protein in the absence and presence of said compound; and measuring the level of infection of said target cells to determine the infectivity of said viral particles in the presence and absence of said compound; The method includes:

2. 2. The method of claim 1, wherein the coronavirus is severe acute respiratory syndrome coronavirus 2 (SARS CoV-2).

3. 3. The method of claim 2, wherein the SARS CoV-2 is a mutant strain, and the mutant strain is a delta mutant, an alpha mutant, a beta mutant, a gamma mutant, an epsilon mutant, an eta mutant, an iota mutant, a kappa mutant, a 1.617.3 mutant, a mu mutant, or a zeta mutant.

4. 2. The method of claim 1, wherein the coronavirus is severe acute respiratory syndrome coronavirus (SARS CoV) or seasonal coronavirus NL63.

5. The method according to any one of claims 1 to 4, wherein the viral particle is an HIV pseudovirion.

6. The method of any one of claims 1 to 5, wherein the nAChR is an α7 nAChR.

7. 1. A method for determining the effectiveness of a compound that modulates the production of coronavirus neutralizing antibodies in a subject, the method comprising: expressing angiotensin-converting enzyme 2 receptor (ACE-2) and / or nicotinic acetylcholine receptor (nAChR) receptors on the target cells; contacting said target cells with viral particles comprising at least a portion of said coronavirus spike protein derived from said subject in the absence and presence of (i) a first sample obtained from said subject prior to treatment with said compound, and (ii) a second sample obtained from said subject after treatment with said compound, wherein said first and second samples comprise antibodies; and measuring the level of infection of the target cells to determine a change in the activity or amount of neutralizing antibodies in the first and second samples of the subject to determine the infectivity of the viral particles in the presence of the first subject sample and the second subject sample, wherein the change in the activity or amount of the neutralizing antibodies is detected as a change in the infectivity of the viral particles; The method includes:

8. 8. The method of claim 7, wherein the coronavirus is severe acute respiratory syndrome coronavirus 2 (SARS CoV-2).

9. 9. The method of claim 8, wherein the SARS CoV-2 is a mutant strain, and the mutant strain is a delta mutant, an alpha mutant, a beta mutant, a gamma mutant, an epsilon mutant, an eta mutant, an iota mutant, a kappa mutant, a 1.617.3 mutant, a mu mutant, or a zeta mutant.

10. 8. The method of claim 7, wherein the coronavirus is severe acute respiratory syndrome coronavirus (SARS CoV) or seasonal coronavirus NL63.

11. The method according to any one of claims 7 to 10, wherein the viral particle is an HIV pseudovirion.

12. The method of any one of claims 7 to 11, wherein the nAChR is an α7 nAChR.

13. 1. A method for identifying a compound capable of modulating a coronavirus infection, the method comprising: (a) into a producer cell, i) a nucleic acid encoding a coronavirus spike protein or a portion thereof, and ii) a genomic viral expression vector that includes sequences derived from a second virus that is not a coronavirus and that includes an indicator nucleic acid that produces a detectable signal; transfecting the (b) incubating the transfected producer cells under conditions that allow pseudovirions containing the coronavirus spike protein or portion thereof to be produced; (c) contacting the pseudovirions of step (b) with a target cell under conditions that allow the pseudovirions to infect the target cell, and in the presence or absence of the compound, wherein the target cell expresses an angiotensin-converting enzyme 2 receptor (ACE-2) and / or a nicotinic acetylcholine receptor (nAChR); and (d) measuring the amount of a detectable signal produced by the target cell to determine the infectivity of the viral particle in the presence or absence of the compound; The method includes:

14. 14. The method of claim 13, wherein the coronavirus is severe acute respiratory syndrome coronavirus 2 (SARS CoV-2).

15. 15. The method of claim 14, wherein the SARS CoV-2 is a mutant strain, and the mutant strain is a delta mutant, an alpha mutant, a beta mutant, a gamma mutant, an epsilon mutant, an eta mutant, an iota mutant, a kappa mutant, a 1.617.3 mutant, a mu mutant, or a zeta mutant.

16. 14. The method of claim 13, wherein the coronavirus is severe acute respiratory syndrome coronavirus (SARS CoV) or seasonal coronavirus NL63.

17. The method of any one of claims 13 to 16, wherein the nAChR is an α7 nAChR.

18. The method of any one of claims 13 to 17, wherein the second virus is HIV or a genetically modified HIV.

19. The method of any one of claims 13 to 18, wherein the compound is a nAChR antagonist.

20. 1. A method for determining the effectiveness of a compound that modulates the production of coronavirus neutralizing antibodies in a subject, the method comprising: (a) into a producer cell, i) a nucleic acid encoding a coronavirus spike protein or a portion thereof derived from the subject; and ii) a genomic viral expression vector that includes sequences derived from a second virus that is not a coronavirus and that includes an indicator nucleic acid that produces a detectable signal; transfecting the (b) incubating the transfected producer cells under conditions that cause the producer cells to produce pseudovirions that contain the coronavirus spike protein or portion thereof; (c) contacting the pseudovirions of step (b) with target cells in the presence or absence of (i) a first sample obtained from the subject prior to treatment with the compound, and (ii) a second sample obtained from the subject after treatment with the compound, wherein the target cells express angiotensin-converting enzyme 2 receptors (ACE-2) and / or nicotinic acetylcholine receptors (nAChR) under conditions that allow the pseudovirions to infect the target cells; (d) measuring the amount of detectable signal produced by the target cells in the presence of the first subject sample and the second subject sample to determine a change in neutralizing antibody activity or amount in the first and second samples of the subject, wherein a change in neutralizing antibody activity or amount is detected as a change in infectivity of the viral particles; The method includes:

21. 21. The method of claim 20, wherein the coronavirus is severe acute respiratory syndrome coronavirus 2 (SARS CoV-2).

22. 22. The method of claim 21, wherein the SARS CoV-2 is a mutant strain, and the mutant strain is a delta mutant, an alpha mutant, a beta mutant, a gamma mutant, an epsilon mutant, an eta mutant, an iota mutant, a kappa mutant, a 1.617.3 mutant, a mu mutant, or a zeta mutant.

23. 21. The method of claim 20, wherein the coronavirus is severe acute respiratory syndrome coronavirus (SARS CoV) or seasonal coronavirus NL63.

24. The method of any one of claims 20 to 23, wherein the nAChR is an α7 nAChR.

25. The method of any one of claims 20 to 24, wherein the second virus is HIV.

26. The method of any one of claims 20 to 25, wherein the compound is a nAChR antagonist.

27. A composition for the detection of compounds capable of modulating coronavirus infectivity, said composition comprising cells genetically modified to be either producer cells or target cells.

28. 28. The composition of claim 27, wherein the coronavirus is severe acute respiratory syndrome coronavirus 2 (SARS CoV-2).

29. 29. The composition of claim 28, wherein the SARS CoV-2 is a mutant strain, and the mutant strain is a delta mutant, an alpha mutant, a beta mutant, a gamma mutant, an epsilon mutant, an eta mutant, an iota mutant, a kappa mutant, a 1.617.3 mutant, a mu mutant, or a zeta mutant.

30. 28. The composition of claim 27, wherein the coronavirus is severe acute respiratory syndrome coronavirus (SARS CoV) or seasonal coronavirus NL63.

31. 31. The composition of any one of claims 27 to 30, comprising a first cell genetically modified to be a target cell expressing angiotensin converting enzyme 2 receptor (ACE-2) and / or nicotinic acetylcholine receptor (nAChR) receptors.

32. 2. A composition according to any preceding or succeeding claim, wherein the target cells are genetically modified to also express human airway transmembrane trypsin-like serine protease (TMPRSS2).

33. The producer cell comprises: i) a coronavirus spike protein or a portion thereof; and ii) a second virus or portion thereof that is not a coronavirus and that includes an indicator nucleic acid that produces a detectable signal; a genetically modified second cell expressing A composition according to any one of the preceding or following claims.

34. 34. The composition of claim 33, wherein the coronavirus is severe acute respiratory syndrome coronavirus 2 (SARS CoV-2).

35. 35. The composition of claim 34, wherein the SARS CoV-2 is a mutant strain, and the mutant strain is a delta mutant, an alpha mutant, a beta mutant, a gamma mutant, an epsilon mutant, an eta mutant, an iota mutant, a kappa mutant, a 1.617.3 mutant, a mu mutant, or a zeta mutant.

36. 34. The composition of claim 33, wherein the coronavirus is severe acute respiratory syndrome coronavirus (SARS CoV) or seasonal coronavirus NL63.

37. A system comprising a station and / or genetically modified cells for performing any of the steps of the method according to claims 1 to 26 or for using any one of the compositions according to claims 27 to 36.

38. A computer program product tangibly embodied in a non-transitory machine-readable storage medium comprising instructions configured to perform any of the steps of the method of claims 1-26, to use any one of the compositions of claims 27-36, or to execute any part of the system of claim 37.

39. A compound identified by any of the methods according to claims 1 to 26, or using any one of the compositions according to claims 27 to 36, or the system according to claim 37, or the computer program system according to claim 38.

40. A composition for treatment in a subject or patient, the composition comprising a compound according to claim 39 for reducing or preventing symptoms of coronavirus infection.

41. 41. The composition of claim 40, wherein the coronavirus is severe acute respiratory syndrome coronavirus 2 (SARS CoV-2).

42. 42. The composition of claim 41, wherein the SARS CoV-2 is a mutant strain, and the mutant strain is a delta mutant, an alpha mutant, a beta mutant, a gamma mutant, an epsilon mutant, an eta mutant, an iota mutant, a kappa mutant, a 1.617.3 mutant, a mu mutant, or a zeta mutant.

43. 41. The composition of claim 40, wherein the coronavirus is severe acute respiratory syndrome coronavirus (SARS CoV) or seasonal coronavirus NL63.

44. A composition for treatment in a subject or patient, said composition comprising an inhibitor that interferes with the binding or interaction of a coronavirus with an AchR receptor in said subject or patient.

45. 45. The composition of claim 44, wherein the AchR receptor is a cholinergic receptor nicotinic alpha 7 subunit (CHRNA7).

46. 46. ​​The composition of claim 45, wherein the coronavirus is severe acute respiratory syndrome coronavirus 2 (SARS CoV-2).

47. 47. The composition of claim 46, wherein the SARS CoV-2 is a mutant strain, and the mutant strain is a delta mutant, an alpha mutant, a beta mutant, a gamma mutant, an epsilon mutant, an eta mutant, an iota mutant, a kappa mutant, a 1.617.3 mutant, a mu mutant, or a zeta mutant.

48. 46. ​​The composition of claim 45, wherein the coronavirus is severe acute respiratory syndrome coronavirus (SARS CoV) or seasonal coronavirus NL63.